TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10480613

Group type: EXPERIMENTAL
Intervention: N(G)‐monomethyl‐L‐arginine (L‐NMMA); total dose 5 mg/kg body weight
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: L-Arginine (5 mg/kg body weight) co-infused during the final 5 min of each exercise bout
Number of subjects: 7
Study: 9592304

Group type: EXPERIMENTAL
Intervention: Clarithromycin (Cla) 500 mg b.i.d and Furazolidone (Fur) 200 mg b.i.d plus CBS 240 mg b.i.d (group I A)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Clarithromycin (Cla) 500 mg b.i.d and Furazolidone (Fur) 200 mg b.i.d plus Lan 30 mg b.i.d (group I B)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Clarithromycin (Cla) 250 mg b.i.d and Furazolidone (Fur) 100 mg b.i.d plus CBS 240 mg b.i.d (group II A)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Clarithromycin (Cla) 250 mg b.i.d and Furazolidone (Fur) 100 mg b.i.d plus Lan 30 mg q.d (group II B)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Phase one study (all groups)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Phase two study (all groups)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Clarithromycin (Cla) resistance
Number of subjects: 88
Study: 2063703

Group type: EXPERIMENTAL
Intervention: Saliva samples returned by mail
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saliva samples returned by interviewers
Number of subjects: 0
Study: 6138642

Group type: EXPERIMENTAL
Intervention: HBIG plus hepatitis B vaccine
Number of subjects: 159

Group type: COMPARATOR
Intervention: HBIG alone
Number of subjects: 159

Group type: COMPARATOR
Intervention: Vaccination alone
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 159
Study: 30452284

Group type: EXPERIMENTAL
Intervention: HIIex (High-Intensity Interval Exercise)
Number of subjects: 15

Group type: COMPARATOR
Intervention: MICex (Moderate-Intensity Continuous Exercise)
Number of subjects: 15

Group type: COMPARATOR
Intervention: REST (Control)
Number of subjects: 15
Study: 29629506

Group type: EXPERIMENTAL
Intervention: Community-based parenting program with group sessions and individualised home coaching
Number of subjects: 1447

Group type: COMPARATOR
Intervention: Community-based parenting program without individualised home coaching
Number of subjects: 1447
Study: 27157024

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Online self-help intervention
Number of subjects: 34
Study: 24919974

Group type: EXPERIMENTAL
Intervention: Anti-platelets
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Combination of all four drug classes
Number of subjects: 259

Group type: COMPARATOR
Intervention: Age ≥75 years
Number of subjects: 259

Group type: COMPARATOR
Intervention: Ten or more visits with general practitioners (GPs) over 1 year
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Drug use at discharge
Number of subjects: 259
Study: 21955873

Group type: EXPERIMENTAL
Intervention: SST (web-based support skills training)
Number of subjects: 40

Group type: COMPARATOR
Intervention: HE (health education)
Number of subjects: 40
Study: 19926841

Group type: EXPERIMENTAL
Intervention: t‐PA
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 17416151

Group type: EXPERIMENTAL
Intervention: Hospital at home and early discharge schemes
Number of subjects: 0
Study: 15118827

Group type: EXPERIMENTAL
Intervention: Relapsing-remitting multiple sclerosis (RRMS) patients
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Secondary progressive multiple sclerosis (SPMS) patients
Number of subjects: 103
Study: 11590629

Group type: EXPERIMENTAL
Intervention: Three-stage clinical trial design
Number of subjects: 21

Group type: COMPARATOR
Intervention: Traditional randomized trial design
Number of subjects: 21
Study: 9829873

Group type: EXPERIMENTAL
Intervention: Long questionnaire (76-item, 16-page)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short questionnaire (16-item, 4-page)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monetary incentive
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second mailing of a questionnaire
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postcard reminder
Number of subjects: 0
Study: 7858505

Group type: EXPERIMENTAL
Intervention: 7‐3‐7 arm (cytosine arabinoside 100 mg/m2 continuous infusion for 7 days and daunorubicin 50 mg/m2 IV day 1‐3 plus etoposide 75 mg/m2 IV days 1‐7)
Number of subjects: 264

Group type: COMPARATOR
Intervention: 7‐3 arm (cytosine arabinoside 100 mg/m2 continuous infusion for 7 days and daunorubicin 50 mg/m2 IV day 1‐3)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 264
Study: 2575630

Group type: EXPERIMENTAL
Intervention: Pre-operative bathing with chlorhexidine in 6 patients
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no chlorhexidine bathing)
Number of subjects: 15
Study: 911218

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cyclazocine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31049999

Group type: EXPERIMENTAL
Intervention: Unequal randomization designs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optimal allocation designs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Restricted randomization procedures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical inference following randomization procedures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General findings from literature
Number of subjects: 0
Study: 28096000

Group type: EXPERIMENTAL
Intervention: 5% glutamine oral care
Number of subjects: 88

Group type: COMPARATOR
Intervention: 2% chlorhexidine gluconate solution oral care
Number of subjects: 88
Study: 25452013

Group type: EXPERIMENTAL
Intervention: Manual cervical distraction without visual feedback
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Manual cervical distraction with visual feedback
Number of subjects: 48
Study: 24119736

Group type: EXPERIMENTAL
Intervention: Combined immunoprophylaxis (200 IU HBIG and 5 or 10 mug yeast recombinant hepatitis B vaccine)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: 10 mug hepatitis B vaccine
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: 5 mug hepatitis B vaccine
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Combined immunoprophylaxis (5 mug and 10 mug hepatitis B vaccine)
Number of subjects: 269
Study: 21612742

Group type: COMPARATOR
Intervention: Propiverine hydrochloride (30 mg s.i.d.)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Propiverine hydrochloride (15 mg t.i.d.)
Number of subjects: 48
Study: 19848050

Group type: EXPERIMENTAL
Intervention: Camel milk
Number of subjects: 24
Study: 16972810

Group type: EXPERIMENTAL
Intervention: Implementation intentions intervention to plan overcoming barriers to attending mammography (specific barriers: changing appointment, arranging transport, negotiating time off work)
Number of subjects: 2082

Group type: COMPARATOR
Intervention: Assessment-only condition (completed a questionnaire about mammography)
Number of subjects: 2082

Group type: COMPARATOR
Intervention: Nonassessment control condition (mere contact with the research team)
Number of subjects: 2082
Study: 15381866

Group type: EXPERIMENTAL
Intervention: fMRI
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: [15O]-H2O-PET
Number of subjects: 25

Group type: COMPARATOR
Intervention: fMRI and [15O]-H2O-PET
Number of subjects: 25
Study: 11257243

Group type: EXPERIMENTAL
Intervention: Activated charcoal treatment during the 4th cycle
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control cycle (3rd cycle) with Minulet and Econ/30
Number of subjects: 13
Study: 9309267

Group type: EXPERIMENTAL
Intervention: High dosage antimony (20 mg/kg/day)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Low dosage antimony (5 mg/kg/day)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Both groups (5 mg/kg/day and 20 mg/kg/day)
Number of subjects: 23
Study: 8214997

Group type: EXPERIMENTAL
Intervention: 1.4 g/d gammalinolenic acid in borage seed oil
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (cotton seed oil)
Number of subjects: 37
Study: 2894994

Group type: EXPERIMENTAL
Intervention: metoprolol 100 mg b.d.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: epanolol 100 mg b.d.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: epanolol 200 mg b.d.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 10
Study: 31707724

Group type: EXPERIMENTAL
Intervention: Gestational diabetes mellitus treatment (diet, monitoring, ± insulin)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Metformin (started early)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: First trimester hemoglobin A1c (5.9‐6.4%)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: First trimester hemoglobin A1c (5.7‐6.4%)
Number of subjects: 5
Study: 30875151

Group type: EXPERIMENTAL
Intervention: Probiotic cake (Bacillus coagulans) consumed for 1 week
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Regular cake consumed for 1 week
Number of subjects: 40

Group type: COMPARATOR
Intervention: Probiotic cake and Regular cake
Number of subjects: 40
Study: 28282381

Group type: EXPERIMENTAL
Intervention: CEA blood test at a threshold of 5μg/L
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: CEA blood test at a threshold of 2.5μg/L
Number of subjects: 582
Study: 25427243

Group type: EXPERIMENTAL
Intervention: Intracoronary injection of human umbilical cord mesenchymal stem cells (low-dose 3x10^6, mid-dose 4x10^6, high-dose 5x10^6)
Number of subjects: 15
Study: 23735408

Group type: EXPERIMENTAL
Intervention: Patient self-monitoring with self-titration of antihypertensives
Number of subjects: 16
Study: 22099892

Group type: EXPERIMENTAL
Intervention: NEC for 2 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: NEC for 8 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: MTA for 2 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: MTA for 8 weeks
Number of subjects: 32
Study: 18584303

Group type: EXPERIMENTAL
Intervention: Intervention group (I) participated in focus group and role play at 2 and 4 months after recruitment.
Number of subjects: 292

Group type: COMPARATOR
Intervention: Control group (C) received oral information.
Number of subjects: 292
Study: 16978740

Group type: EXPERIMENTAL
Intervention: Initial submissions of RCTs
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Published articles
Number of subjects: 62

Group type: COMPARATOR
Intervention: BMJ external peer review process
Number of subjects: 62
Study: 15584811

Group type: EXPERIMENTAL
Intervention: Experience-based JOLs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Theory-based JOLs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manipulated retention interval
Number of subjects: 0
Study: 12536592

Group type: EXPERIMENTAL
Intervention: Clindamycin suppository
Number of subjects: 80

Group type: COMPARATOR
Intervention: Metronidazole suppository
Number of subjects: 80
Study: 9426669

Group type: EXPERIMENTAL
Intervention: External ultrasonic tumescent liposuction (10 minutes of preoperative ultrasound therapy)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: External ultrasonic tumescent liposuction
Number of subjects: 10
Study: 8275064

Group type: EXPERIMENTAL
Intervention: High intensity cognitive-behavioral group psychotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early abstinence cognitive-behavioral group psychotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of high intensity and early abstinence cognitive-behavioral group psychotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weekly psychotherapy using manual-based cognitive-behavioral therapy
Number of subjects: 0
Study: 2872874

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Visible vessel group
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Surgery group (visible vessel)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Conservative measures group (visible vessel)
Number of subjects: 96
Study: 30566007

Group type: EXPERIMENTAL
Intervention: Metformin 2000 mg daily for 3 months
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 28479901

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for 12 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: No exercise training for 12 weeks
Number of subjects: 80
Study: 25131356

Group type: EXPERIMENTAL
Intervention: Dobutamine hydrochloride 2μgkg(‐1)min(‐1)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Dobutamine hydrochloride 4μgkg(‐1)min(‐1)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Dobutamine hydrochloride 6μgkg(‐1)min(‐1)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (saline infusion)
Number of subjects: 124
Study: 23006861

Group type: EXPERIMENTAL
Intervention: Three 20-min sessions/wk
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: One 20-min session/wk
Number of subjects: 60

Group type: COMPARATOR
Intervention: No balance training (control)
Number of subjects: 60
Study: 21199787

Group type: EXPERIMENTAL
Intervention: 320 mg magnesium/day as magnesium citrate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (sodium citrate)
Number of subjects: 100
Study: 18793926

Group type: EXPERIMENTAL
Intervention: White mineral trioxide aggregate (MTA) used as a root‐end filling material exposed to pH 4.4 for 3 days
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: White mineral trioxide aggregate (MTA) used as a root‐end filling material exposed to pH 5.4 for 3 days
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: White mineral trioxide aggregate (MTA) used as a root‐end filling material exposed to pH 6.4 for 3 days
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: White mineral trioxide aggregate (MTA) used as a root‐end filling material exposed to pH 7.4 for 3 days
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (root‐end cavities not filled)
Number of subjects: 70
Study: 11431298

Group type: EXPERIMENTAL
Intervention: Cranberry-lingonberry juice (50 ml daily for six months)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG drink (100 ml five days a week for one year)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 150
Study: 9923579

Group type: EXPERIMENTAL
Intervention: PcV (conventional phenoxymethylpenicillin tablet)
Number of subjects: 24

Group type: COMPARATOR
Intervention: PcVsr (saliva-resistant coated tablet)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both formulations (PcV and PcVsr)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: PcVsr
Number of subjects: 24

Group type: COMPARATOR
Intervention: PcV
Number of subjects: 24
Study: 8155443

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 26

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 26
Study: 3075601

Group type: EXPERIMENTAL
Intervention: Nicardipine (40 mg/day)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg/day)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Nicardipine (40 mg) during acute oral test
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg) during acute oral test
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 95
Study: 31419349

Group type: EXPERIMENTAL
Intervention: Higher BCC genetic risk score
Number of subjects: 604
Study: 30482494

Group type: EXPERIMENTAL
Intervention: Major ventricular arrhythmias (VAs) developed in 105 patients (5.1%).
Number of subjects: 2074

Group type: EXPERIMENTAL
Intervention: Symptoms of depression present in 22.2% of patients at baseline, declined to 14.1% at 1 month post-discharge.
Number of subjects: 2074

Group type: EXPERIMENTAL
Intervention: Symptoms of anxiety present in 23.5% of patients at baseline, declined to 12.6% at 1 month post-discharge.
Number of subjects: 2074

Group type: EXPERIMENTAL
Intervention: PHQ-2 and GAD-2 scores were used to measure symptoms at 3, 6, and 12 months.
Number of subjects: 2074
Study: 28339847

Group type: EXPERIMENTAL
Intervention: Exercise advice in addition to existing care (5-10 calls over 6 months from a physical therapist trained in behavior change support)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Existing care (minimum of one phone call from a nurse for advice on OA self-management)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Exercise advice in addition to existing care
Number of subjects: 175

Group type: COMPARATOR
Intervention: Existing care
Number of subjects: 175
Study: 25365531

Group type: EXPERIMENTAL
Intervention: Veracity test method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Behavioral indicator recognition
Number of subjects: 0
Study: 23885659

Group type: EXPERIMENTAL
Intervention: Multiple antenatal contraceptive counselling sessions
Number of subjects: 216

Group type: COMPARATOR
Intervention: Single postnatal counselling session
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Antenatal group (previously undecided patients)
Number of subjects: 216
Study: 21554920

Group type: EXPERIMENTAL
Intervention: Artglass composite resin inlays
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Charisma composite resin inlays
Number of subjects: 89

Group type: COMPARATOR
Intervention: Both inlay systems
Number of subjects: 89
Study: 17416370

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16866581

Group type: EXPERIMENTAL
Intervention: Emotional Stroop task
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Recognition task
Number of subjects: 152

Group type: COMPARATOR
Intervention: Dot-probe task
Number of subjects: 152
Study: 12700295

Group type: EXPERIMENTAL
Intervention: Methylprednisolone pulse therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10828926

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Delayed surgery after conservative treatment
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Randomized surgical treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Randomized conservative treatment
Number of subjects: 100
Study: 9322620

Group type: EXPERIMENTAL
Intervention: Active electrical device
Number of subjects: 121

Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 121
Study: 8223847

Group type: EXPERIMENTAL
Intervention: Carvedilol 25-50 mg o.d. (n = 116)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Captopril 25-50 mg o.d. (n = 117)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Carvedilol
Number of subjects: 250

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 250
Study: 31599919

Group type: EXPERIMENTAL
Intervention: Ketone monoester drink (0.45 mL/kg body weight)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ketone monoester drink
Number of subjects: 15
Study: 28830293

Group type: EXPERIMENTAL
Intervention: Escalated treatment plan (mean doses up to 95 Gy/33 fractions for tumor and 74 Gy/33 fractions for lymph nodes)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard treatment plan
Number of subjects: 27
Study: 26708778

Group type: EXPERIMENTAL
Intervention: Scheduled TMS (SCH)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Observation only (OBS)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Overall study completion
Number of subjects: 49
Study: 25183043

Group type: EXPERIMENTAL
Intervention: Motivational interviewing-based, individualized counseling and referral intervention for physical activity promotion
Number of subjects: 340
Study: 22298571

Group type: EXPERIMENTAL
Intervention: UNIMMAP (prenatal multiple micronutrients)
Number of subjects: 1056

Group type: EXPERIMENTAL
Intervention: Cumulative Micronutrient Intake (CMI)
Number of subjects: 1056

Group type: COMPARATOR
Intervention: UNIMMAP and IFA
Number of subjects: 1056
Study: 20298571

Group type: EXPERIMENTAL
Intervention: Multiple micronutrients (MM) with vitamin A
Number of subjects: 393

Group type: COMPARATOR
Intervention: Vitamin A plus zinc (VAZ)
Number of subjects: 393

Group type: COMPARATOR
Intervention: Vitamin A (VA)
Number of subjects: 393
Study: 18204338

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg once daily
Number of subjects: 311

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study: 16313986

Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 14656612

Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 2457

Group type: COMPARATOR
Intervention: Noninvasive strategy
Number of subjects: 2457

Group type: COMPARATOR
Intervention: Noninvasive strategy with revascularization
Number of subjects: 2457

Group type: COMPARATOR
Intervention: Noninvasive strategy without revascularization
Number of subjects: 2457
Study: 11035617

Group type: EXPERIMENTAL
Intervention: Closed cohort analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Open cohort analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follow-up
Number of subjects: 0
Study: 8977599

Group type: EXPERIMENTAL
Intervention: Budesonide 800 micrograms twice daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 1600052

Group type: EXPERIMENTAL
Intervention: Lansoprazole 10 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Lansoprazole 20 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg (morning dosing)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Lansoprazole 30 mg (evening dosing)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Lansoprazole (all doses)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 3917659

Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Nitroprusside
Number of subjects: 33